Glucose Disposal & Insulin Sensitivity
In a randomized, placebo-controlled study of type 2 diabetic patients on metformin, ATX-304 markedly reduced fasting plasma glucose and HOMA-IR, confirming its capacity to suppress hepatic gluconeogenesis and enhance skeletal-muscle glucose uptake via AMPK activation [1].
Lipid & Cardiovascular Support
Preclinical data demonstrate that ATX-304 reduces hepatocellular lipid droplets, alleviates steatosis, and improves vascular markers—effects visualized by histological clearance of liver lipid accumulation and enhanced endothelial function in murine models [2].
Mitochondrial Energy Metabolism
In aged mice, chronic ATX-304 treatment stimulated AMPK-mediated mitochondrial biogenesis, leading to increased cardiac output, improved microvascular perfusion, and greater exercise capacity—mirroring key benefits of endurance training without exercise [3][4].
References
- AMPK activated protein kinase in T2D: https://pubmed.ncbi.nlm.nih.gov/29925691/
- ATX-304 clears liver lipid droplets & improves endothelial function: https://insight.jci.org/articles/view/179990/figure/2
- ATX-304 exercise-mimetic effects in aged mice: https://pubmed.ncbi.nlm.nih.gov/29925691/
- Age-related metabolic improvements in mice: https://www.nature.com/articles/s42003-021-02837-0
Note: BioAmp is supplied strictly for investigational research use only.
